Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

HLA-A*11:01 (Monomer) protein (KRAS G12A)

Origine: Humain Hôte: HEK-293 Cells Recombinant > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
N° du produit ABIN7454279
  • Antigène
    HLA-A*11:01
    Type de proteíne
    Recombinant
    Attributs du protein
    Monomer
    Origine
    Humain
    Source
    • 31
    • 6
    • 1
    HEK-293 Cells
    Purification/Conjugué
    KRAS G12A
    Fonction
    Human HLA-A*11:01 & B2M & KRAS G12A (VVVGAAGVGK) Monomer Protein
    Séquence
    Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVVGAAGVGK peptide
    Specificité
    Uni-Prot: AAV53343.1 (HLA-A*11:01), , P61769 (B2M), VVVGAAGVGK
    Attributs du produit
    Recombinant Human HLA-A*11:01 & B2M & KRAS G12A (VVVGAAGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAAGVGK peptide.
    Pureté
    > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
    Stérilité
    0.22 μm filtered
    niveau d'endotoxine
    Less than 1EU per μg by the LAL method.
  • Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.
    Buffer
    Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.
    Stock
    -20 °C,-80 °C
    Stockage commentaire
    -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Date de péremption
    12 months
  • Antigène
    HLA-A*11:01
    Sujet
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    Poids moléculaire
    50.30 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Tris-Bis PAGE result.
Vous êtes ici:
Support technique